BAKER BROS. ADVISORS LP Q3 2020 Filing
Filed November 16, 2020
Portfolio Value
$25.0B
Holdings
120
Report Date
Q3 2020
Filing Type
13F-HR
All Holdings (120 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —Dicerna Pharmaceuticals, Inc. | 113,135 | $2.0B | 8.13% | |
| 102 | RCUSArcus Biosciences, Inc. | 115,425 | $2.0B | 7.90% | |
| 103 | NGMUSDNGM Biopharmaceuticals, Inc. | 118,100 | $1.9B | 7.51% | |
| 104 | GLPGGalapagos NV | 12,412 | $1.8B | 7.04% | |
| 105 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $1.6B | 6.54% | |
| 106 | —Molecular Templates, Inc. | 148,817 | $1.6B | 6.49% | |
| 107 | OYSTOyster Point Pharma, Inc. | 68,228 | $1.4B | 5.75% | |
| 108 | ORTXUSDOrchard Therapeutics plc | 343,202 | $1.4B | 5.64% | |
| 109 | CPRXCatalyst Pharmaceuticals, Inc. | 474,400 | $1.4B | 5.63% | |
| 110 | —Genetron Holdings Limited | 100,000 | $1.2B | 4.77% | |
| 111 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $1.1B | 4.43% | |
| 112 | —Evofem Biosciences, Inc. | 433,048 | $1.0B | 4.08% | |
| 113 | APLTApplied Therapeutics, Inc. | 38,034 | $790.0M | 3.16% | |
| 114 | GLMDGalmed Pharmaceuticals Ltd. | 205,375 | $725.0M | 2.90% | |
| 115 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $679.0M | 2.71% | |
| 116 | —Adamas Pharmaceuticals, Inc. | 163,830 | $675.0M | 2.70% | |
| 117 | —Affimed N.V. | 189,800 | $643.0M | 2.57% | |
| 118 | VSAREURAravive, Inc. | 75,854 | $357.0M | 1.43% | |
| 119 | GNFTYGenfit SA | 28,396 | $150.0M | 0.60% | |
| 120 | —Sunesis Pharmaceuticals, Inc. | 53,066 | $66.0M | 0.26% |
PreviousPage 2 of 2